DEXAMETHASONE - dexamethasone injection, solution VetTek

DEXAMETHASONE INJECTION 2 mg/mL DEXAMETHASONE STERILE INJECTION

Solution for intravenous or intramuscular injection

Veterinary

CAUTION

Federal Law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION

DEXAMETHASONE INJECTION 2 mg/mL is a synthetic analogue of prednisolone, having similar but more potent anti-inflammatory therapeutic action and diversified hormonal and metabolic effects. Modification of the basic corticoid structure as achieved in DEXAMETHASONE INJECTION 2 mg/mL offers enhanced anti-inflammatory effect compared to older corticosteroids. The dosage of DEXAMETHASONE INJECTION 2 mg/mL required is markedly lower than that of prednisone and prednisolone.

DEXAMETHASONE INJECTION 2 mg/mL is not species-specific; however, the veterinarian should read the sections on **INDICATIONS**, **DOSAGE**, **SIDE EFFECTS**, **CONTRAINDICATIONS**, **PRECAUTIONS**, and **WARNINGS** before this drug is used.

DEXAMETHASONE INJECTION 2 mg/mL is intended for *intravenous or intramuscular* administration. Each mL contains 2 mg dexamethasone, 500 mg polyethylene glycol 400, 9 mg benzyl alcohol, 1.8 mg methylparaben and 0.2 mg propylparaben as preservatives, 4.75% alcohol, HCl to adjust pH to approximately 4.9, water for injection q.s.

EXPERIMENTAL STUDIES

Experimental animal studies on dexamethasone have revealed it possesses greater anti-inflammatory activity than many steroids. Veterinary clinical evidence indicates dexamethasone has approximately twenty times the anti-inflammatory activity of prednisolone and seventy to eighty times that of hydrocortisone. Thymus involution studies show dexamethasone possesses twenty-five times the activity of prednisolone. In reference to mineralocorticoid activity, dexamethasone does not cause significant sodium or water retention. Metabolic balance studies show that animals on controlled and limited protein intake will exhibit nitrogen losses on exceedingly high dosages.

INDICATIONS

DEXAMETHASONE INJECTION 2 mg/mL is indicated for the treatment of primary bovine ketosis and as an anti-inflammatory agent in the bovine and equine.

As supportive therapy, DEXAMETHASONE INJECTION 2 mg/mL may be used in the management of various rheumatic, allergic, dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids. DEXAMETHASONE INJECTION 2 mg/mL may be used intravenously as supportive therapy when an immediate hormonal response is required.

Bovine Ketosis

DEXAMETHASONE INJECTION 2 mg/mL is offered for the treatment of primary ketosis. The gluconeogenic effects of DEXAMETHASONE INJECTION 2 mg/mL, when administered intramuscularly, are generally noted within the first 6 to 12 hours. When DEXAMETHASONE

INJECTION 2 mg/mL is used intravenously, the effects may be noted sooner. Blood sugar levels rise to normal levels rapidly and generally rise to above normal levels within 12 to 24 hours. Acetone bodies are reduced to normal concentrations usually within 24 hours. The physical attitude of animals treated with DEXAMETHASONE INJECTION 2 mg/mL brightens and appetite improves, usually within 12 hours. Milk production, which is suppressed as a compensatory reaction in this condition, begins to increase. In some instances, it may even surpass previous peaks. The recovery process usually takes from 3 to 7 days.

Supportive Therapy

DEXAMETHASONE INJECTION 2 mg/mL may be used as supportive therapy in mastits, metritis, traumatic gastritis, and pyelonephritis, while appropriate primary therapy is administered. In these cases, the corticosteroid combats accompanying stress and enhances the feeling of general well-being. DEXAMETHASONE INJECTION 2 mg/mL may also be used as supportive therapy in inflammatory conditions, such as arthritic conditions, snake bite, acute mastitis, shipping fever, pneumonia, laminitis, and retained placenta.

Equine

DEXAMETHASONE INJECTION 2 mg/mL is indicated for the treatment of acute musculoskeletal inflammations, such as bursitis, carpitis, osselets, tendonitis, myositis, and sprains. If boney changes exist in any of the conditions, joints, or accessory structures, responses to DEXAMETHASONE INJECTION 2 mg/mL cannot be expected. In addition, DEXAMETHASONE INJECTION 2 mg/mL may be used as supportive therapy in fatigue, heat exhaustion, influenza, laminitis, and retained placenta provided that the primary cause is determined and corrected.

ADMINISTRATION AND DOSAGE

Therapy with DEXAMETHASONE INJECTION 2 mg/mL, as with any other potent corticosteroid, should be individualized according to the severity of the condition being treated, anticipated duration of steroid therapy, and teh animal's threshold or tolerance for steroid excess.

Treatment may be changed over to DEXAMETHASONE INJECTION2 mg/mL from any other glucocorticoid with proper reduction or adjustment of dosage.

Bovine - DEXAMETHASONE INJECTION 2 mg/mL - 5 to 20 mg intravenously or intramuscularly.

Dexamethasone Powder may be administered or the parenteral dose repeated as needed.

Equine - DEXAMETHASONE INJECTION 2 mg/mL - 2.5 to 5 mg intravenously or intramuscularly.

Dexamethasone Powder may be administered or the parenteral dose repeated as needed.

CONTRAINDICATIONS

Except for emergency therapy, do not use in animals with chronic nephritis and hypercorticalism (Cushing's syndrome). Existence of congestive heart failure, diabetes, and osteoporosis are relative contraindications. Do not use in viral infections during the viremic stage.

PRECAUTIONS

Animals receiving DEXAMETHASONE INJECTION 2 mg/mL should be under close observation. Because of the anti-inflammatory action of corticosteroids, signs of infection may be masked and it may be necessary to stop treatment until a further diagnosis is made. Overdosage of some glucocorticoids may result in sodium retention, fluid retention, potassium loss, and weight gain.

DEXAMETHASONE INJECTION 2 mg/mL may be administered to animals with acute or chronic bacterial infections providing the infections are controlled with appropriate antibiotic or chemotherapeutic agents.

Doses greater than those recommended in horses may produce a transient drowsiness or lethargy in some horses. The lethargy usually abates in 24 hours.

Use of corticosteroids, depending on dose, duration, and specific steroid, may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapid acting corticosteroid should be considered in unusually stressful situations.

WARNINGS

Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate parturition followed by dystocia, fetal death, retained placenta, and metritis.

Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have produced cleft palate. Other congenital anomalies including deformed forelegs phocomelia, and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy.

A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

SIDE EFFECTS

Side effects, such as SAP and SGPT enzyme elevations, weight loss, anorexia, polydipsia, and polyuria have occurred following the use of synthetic corticosteroids in dogs. Vomiting and diarrhea (occasionally bloody) have been observed in dogs and cats.

Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.

Corticosteroids reportedly cause laminitis in horses.

HOW SUPPLIED

DEXAMETHASONE INJECTION 2 mg/mL, 100 mL multiple dose vial.

Store at 20°C to 25°C (86°F to 77°F), excursions permitted between 15°C and 30° (between 59°F and 86°F).

Protect from freezing

Each mL contains: 2 mg dexamethasone; 500 mg polyethylene glycol 400; 9 mg benzyl alcohol, 1.8 mg methylparaben, and 0.2 mg propylparaben as preservatives; 4.75% alcohol; HCl to adjust pH to approximately 4.9; water for injection qs.

TAKE TIME OBSERVE LABEL DIRECTIONS

Usual Dose

Bovine-5 to 20 mg Equine-2.5 to 5 mg

A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59° and

Protect from freezing READ ACCOMPANYING DIRECTIONS CAREFULLY

Veterinary

FOR ANIMAL USE ONLY

Caution: Federal law restricts this drug use by or on the order of a licensed veterinarian.

MULTIPLE DOSE VIAL

ANADA 200-324, Approved by FDA



pregnancy and may precipitate parturition followed by dystocia, fetal death, retained placenta, and metritis.

Additionally, controcateroids administered to dogs, rabbits, and rodents during pregnancy have produced cell patter. Other congenital anomalies including deformed forcings phocomelia, and ansarca have been reported in offspring of dogs which received controcateroids during pregnancy.

SIDE EFFECTS
Side officits, such as SAP and SGPT enzyme elevations, weight loss, anomexia, polydipsia, and polyura have occurred following the use of synthetic corticosteroids in digs. Vernibing and dishrint incoastionally bloady) have been observed in dags and

Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid associaturi therapy. Corticosteroids reportedly cause laminitis in horses.

HOW SUPPLIED
DEXAMETHASONE INJECTION 2 mg/mL, 100 mL multiple dose vial.

Store at 20°C to 25°C |68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F).
Protect from freezing

D-2953-04

Distributed by Manufactured by Sparhawk Laboratories, Inc. Blue Springs, MD 64014 Lenexa, KS 66215, USA

ANADA#: 200-324, Approved by FDA

Each mL contains: 2 mg dexameth-asone; 500 mg polyethylene glycol 400; 9 mg benzyl alcohol, 1.8 mg methyl-paraben, and 0.2 mg propylparaben as preservatives; 4.75% alcohol; HCI to adjust pH to approximately 4.9; water for injection qs.

TAKE TIME OBSERVE LABEL DIRECTIONS

VETTEK Blue Springs, MO 64014

Sperhewk Laboratories, Inc. Lenexa, KS 68215, USA

D-2953-04

Rev. 11-11

DEXAMETHASONE INJECTION 2 mg/mL

Solution for intravenous or intramuscular injection Veterinary

CAUTION
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

order of a licensed veterina au.

DESCRIPTION

DESCRIPTION

DESAMETHASONE INJECTION 2 mg/mL is a synthetic enalogue of prednisolores, having similar but more operate rail-inflammatory thereputile scircle and diversified hormonal and metabolic effects as achieved in DESAMETHASONE NUELTION 2 mg/mL offices orihanoze and inflammatory effect companied to reflect software and inflammatory effect companied to DESAMETHASONE NUELTION 2 mg/mL of DESAMETHASONE NUELTION 2 mg/mL required is markedly lower than that of prednisone and

DEXAMETHASONE INJECTION 2 mg/ml. is not special-spacific however, the vectorianian should special-spacific however, the vectorianian should special sp

approximately 4.9, water for injection q.s. EXPERIMENTAL STUDES Experimental arimal studies or desamethesone have revealed it possesses greater anti-inflammatory activity then many steroids. Veterinary clinical exidence indicates desamethesone has approximately twenty times the anti-inflammatory activity of prediscione and eventy to algority times that hydrocorrisons. Thyrmas involution studies above activity of profiscione. In reference to mineralocorrison activity, doxamethasone does not mineralocorrison activity, doxamethasone does not

balance studies show that animals on controlled and limited protein intake will exhibit nitrogen losses on exceedingly high dosages.

NDICATIONS
DEXAMETHASONE INJECTION 2 mg/mL is indicated to a majority of primary bovine ketoeis and as

DEXAMETHASONE INJECTION 2 mg/ml, is indicated for the treatment of primary borine stocks and as a mati-inflammatory agent in the boxine and equire.

As supportive therapy, DEXAMETHASONE INJECTION 2 mg/ml, may be used in the stock of the st

Sovine Katosis

DEVANETHASONE INJECTION 2 mg/mL is offered
for the breakment of primary ketosis. The
gluconagenite effects of DEXANETHASONE
KIJECTION 2 mg/mL, when administered
inframusolarity, are generally noted within the first 6
to 12 hours. When DEVANETHASONE INJECTION 2

mg/mL is used intravenously, the effects may be noted sooner. Blood sugar levels rise to normal levels rapidly and persentily rise to above normal levels rapidly and persentily rise to above normal levels remained constructions essally within 22 hours. National Society and 22 hours are presented over the persentile season of 22 hours. The DECAMETHASONE INJECTION 2 mg/mL hightens and appetite improves, usually within 12 hours. Milk production, which is suppressed as a compensatory reaction in this condition, begins to increase in correction in the condition, begins to increase in correction in the condition, begins to 10 radius; and the personnel processor process could just letter on 10 radius;

recovery process usually latest from 3 to 7 days.

Supportive Prises (NJECTION 2 mg/ml. may be used as supportive therapy in madrils, matrils, used as supportive therapy in madrils, matrils, appropriate primary through its administrant in these cases, the conficionativid combines accompanying stress and enhances the feeling of general well-being. DEXAMETHASOME NILECTION 2 mg/ml. may also be used as supportive therapy in inflammation conditions, such as enthrietic conditions, sinkle bine, acute mastila, shipping feets, presumonia, similate, and retained placetime.

Equint DEMAPETHASONE INJECTION 2 mg/ml. is indicated for the treatment of scute musuclosteletal inflammations, such as burefus, cerpitis, seelests, tendontits, myostits, and sprains. If boney changes east in any of the canditions, plains, or accessory. In the candition of the canditions of the canditions, butting, or accessory. In the COMMAPETHASE of the candition of the candit

corrected.

ADMINISTRATION AND DOSAGE
Therapy with DEXAMETHASONE INJECTION 2
mg/mil, as with any other potent corticostaroid, should be individualized according to the severity of the condition being treated, artitiopated duration of sternial therapy, and the animal's threshold or tolerance for steroid excess.

Treatment may be changed over to DEXAMETHASONE INJECTION 2 mg/mL from any other glucocorricoid with proper reduction or adjustment of dosage.

Bovine - DEXAMETHASONE INJECTION 2 mg/mL - 5 to 20 mg intravenously or intramuscularly.

Dexamethasone Powder may be administered or the parenteral dose repeated as needed.

Equine - DEXAMETHASONE INJECTION 2 mg/mL - 2.5 to 5 mg intravenously or intramuscularly.

Dexamethesone Powder may be administered or the perenteral dose repeated as needed.

parentized dose repeated as needed.

CONTRANDICATIONS

Except for emergency therapy, do not use in animals
with chronic nephritis and hypercordicalism (Cushing's
syndrome). Existence of congestive theart failure,
diabetes, and osteoprocesia are relative
contraindications. Do not use in viral infections during
the viramis stage.

the viremic stage, PERCAUTIONS PERCAUTION 2 Animals modiving DEXAMETHASONE INJECTION 2 Animals modiving DEXAMETHASONE INJECTION 2 animals modified by the control of control of original shauld be under close observation. Because of the anti-inflammatury action of control original signs of infection may be masked and it may be necessary to stop treatment until a further disprocis is made. Overdosse of some glucocordicalids may 6

result in sodium retention, fluid retention, potassium loss, and weight gain.

DEXAMETHASONE INJECTION 2 mg/mL may be administered to animals with acute or chronic bacterial infections providing the infections are controlled with appropriate antibiotic or chemotherapeutic agents.

Doses greater than those recommended in horses may produce a transient drowsiness or lethergy in some horses. The lethergy usually abates in 24 hours.

Use of continesteroids, depending on does, duration, and specific steroid, may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently resolving or resembly withdrawal from systemic confociated dreatments, when the standard draws are standard draws and the considered in unbaselly stressful albustone.

DEXAMETHASONE

dexamethasone injection, solution

Product Information

Product Type	PRESCRIPTION ANIMAL DRUG	Item Code (Source)	NDC:60270-337

Route of Administration INTRAMUSCULAR, INTRAVENOUS

Active Ingredient/Active Moiety

	,			
	Ingredie	nt Name	Basis of Strength	Strength
DEXAMETHA	ASONE (UNII: 7S5I7G3JQL) (DEX	AMETHASONE - UNII:7S5I7G3JQL)	DEXAMETHASONE	2 mg in 1 mL

Packaging

ı						
I	# Item Code	Package Description	Marketing Start Date	Marketing End Date		
I	1 NDC:60270-337-10	100 mL in 1 VIAL, MULTI-DOSE				

Marketing Information

0			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANADA	ANADA200324	01/18/2008	

Labeler - VetTek (056387798)

Revised: 11/2012 VetTek